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abstract
PURPOSE The age at which women present with breast cancer varies widely among nations, and breast cancer
may behave differently in younger women. Differences in clinicopathological characteristics based on age have
not been well characterized in Pakistani patients with breast cancer.
METHODS We conducted a retrospective review of patients with symptoms of breast cancer presenting to Aga
Khan University Hospital (AKUH), a large tertiary care center in Pakistan, between 2001 and 2010; we
compared young (≤ 40 years) versus older (. 40 years) patients in terms of their clinicopathological char-
acteristics. We also compared this Pakistani cohort with the US population using data from the National Cancer
Database (NCDB).
RESULTS A total of 1,334 patients with breast cancer presented to our center over the 10-year review period. The
median age at diagnosis was 50 years, compared with 60 years for patients in the NCDB. In the AKUH cohort,
younger patients were signiﬁcantly more likely than their older counterparts to present with metastatic disease
(13.1% v 10.8%; P, .01). They also weremore likely to present with higher-grade tumors (grade 3: 40.1% v 28.
3%;P, .001), have triple hormone receptor–negative phenotype (25.4% v 14.1%, P, .001), and have positive
axillary lymph node involvement (70.9% v 57.5%; P , .001) compared with older women. Younger and older
patients in the AKUH cohort tended to present with higher-stage disease (P, .001) and weremore likely to have
triple hormone receptor–negative disease (P, .001), compared with all patients in the NCDB and with those of
Indo-Pakistani origin.
CONCLUSION Young Pakistani women, similar to their Western counterparts, present with more advanced
disease and more aggressive tumor biology than their older counterparts.
J Global Oncol. © 2019 by American Society of Clinical Oncology
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INTRODUCTION
Breast cancer is the most common malignancy af-
fecting womenworldwide and one of the leading causes
of cancer-related deaths.1 In the United States, only 5%
to 7% of all breast cancers are diagnosed in patients
younger than 40 years,2-4 whereas in the developing
countries of Asia and Africa, this ﬁgure is reported to be
much higher.5-7 In addition, patients with breast cancer
in low- to middle-income countries (LMICs) tend to
present with advanced-stage disease than those in
countries with higher income levels. The etiology of
these discrepancies between high-income countries
and LMICs in terms of age and stage at presentation is
not well understood; hypotheses include racial and
genetic differences, varying environmental exposures,
diversity in access to screening and treatment, and
differences in population distribution, with the LMICs
having a younger population secondary to lowermedian
life expectancy and higher birth rate.5-7 Patients with
breast cancer who receive a cancer diagnosis at
a young age are more likely to present at an advanced-
stage and with more aggressive disease than their older
counterparts, according to many studies conducted in
Western populations and in other LMICs.8-10 No such
comparison has been reported from Pakistan, to our
knowledge.
In Pakistan, breast cancer is the most common ma-
lignancy affecting women, accounting for approxi-
mately 40% of all malignant tumors in the female
population.11,12 The age distribution of these malig-
nancies and the clinicopathologic features of younger
patients compared with those of older patients in this
population have not been well studied. We sought to
determine whether the clinicopathologic features dif-
ferentiating younger and older patients seen in
Western countries would be found in Pakistan and
whether this could account for the poorer outcomes in
patients with breast cancer in LMICs.
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METHODS
A retrospective record review was conducted of all Pak-
istani patients with breast cancer presenting consecutively
to the Aga Khan University Hospital (AKUH) in Karachi,
Pakistan, between January 1, 2001, and December 31,
2010. Male patients, patients with bilateral breast cancer or
multiple malignancies at presentation, and patients who
were not of Pakistani descent were excluded from the
study. Patients were divided into two groups on the basis of
their age at presentation: a cohort of patients younger than
40 years and a cohort of patients older than 40 years.
Groups were compared for clinicopathologic features.
Staging was performed using the American Joint Com-
mittee on Cancer Cancer Staging Manual, Seventh Edition,
and receptor status was based on standard immunohis-
tochemical staining.
We also compared this Pakistani cohort with the US pop-
ulation, using 2013 data from the National Cancer Database
(NCDB). The NCDB is a joint project of the American College
of Surgeons and the American Cancer Society, which col-
lects data from hospital registry data at more than 1,500
Commission on Cancer–accredited facilities in the United
States. These data represent more than 70% of newly di-
agnosed cancer cases in the United States. Data from the
2013 NCDB for patients with breast cancer were used for
this comparison. We also analyzed differences between the
AKUH cohort and patients of Indo-Pakistani origin in the
NCDB. This study was reviewed and approved by the ethics
review committee of the Aga Khan University. Non-
parametric statistical analyses using Pearson’s χ2 test were
performed using SPSS, version 24.0 (SPSS, Chicago, IL).
RESULTS
A total of 1,334 patients with breast cancer presented to our
center over the 10-year review period. The median age at
diagnosis was 50 years (range, 20 to 92 years); 366 pa-
tients (27.4%) were younger than 40 years at presentation.
The median age at diagnosis in the NCDB was 60 years
(range, 18 to 90 years). The two populations were signif-
icantly different in distribution (P , .001), with the Pak-
istani population tending to present at younger age (Fig 1).
Clinicopathologic characteristics of the younger and older
AKUH cohorts are listed in Table 1. Younger patients tended
to present at a higher-stage disease, with lymph node–
positive, higher-grade cancers that were less likely to be
hormone receptor–positive and more likely to be triple
hormone receptor–negative. Analysis of the NCDB data
revealed similar correlations between younger age
(≤ 40 years) and clinical stage at presentation, lymph
node status, grade, estrogen receptor–positivity, and like-
lihood of having triple hormone receptor–negative disease
(P , .001 for all comparisons).
Compared with patients in the NCDB, younger (Table 2)
and older (Table 3) patients in the AKUH cohort tended to
present at higher-stage disease (P , .001) and were more
likely to have triple-hormone receptor–negative disease
(P , .001). Patients in both Pakistani cohorts were less
likely to present with higher-grade disease than those in the
NCDB (P , .001). Compared with US patients of Indo-
Pakistani origin in the NCDB, patients in the AKUH cohort
were signiﬁcantly more likely to present with advanced-
stage and triple negative disease, and were less likely to
present with high-grade tumors in both the younger
(Table 2) as well as older (Table 3) cohorts.
When patients of Indo-Pakistani origin were compared with
other races in the US population, using the NCDB data,
differences were more evident in the older (. 40 years)
cohort. Older patients of Indo-Pakistani origin were more
likely to present with higher-grade, triple hormone
receptor–negative, node-positive tumors than were older
patients of other races in the United States (Table 4). In
younger patients, however, breast cancer in patients of Indo-
Pakistani origin was of the same stage as other patients, but
the former were more likely to present with triple hormone
receptor–negative disease (Table 4). There was also a trend
for these patients to present with higher-grade tumors.
CONTEXT
Key Objective
To determine the clinicopathological features of breast cancer in young versus older Pakistani women reporting to a large
tertiary care center, and then to compare trends in clinicopathological features of breast cancer in Pakistani women with
those of women with breast cancer in the United States and further with those of Indo-Pakistani origin in the United States.
Knowledge Generated
Of Pakistani women with breast cancer, more than 25% present before the age of 40 years. Furthermore, young Pakistani
women tend to present with more aggressive and advanced disease compared with young women in the United States and
older women in Pakistan.
Relevance
Our ﬁndings warrant greater awareness of cancer risk in young Pakistani women and the consideration of screening for breast
cancer at a younger age in developing countries that have a greater proportion of younger women.
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DISCUSSION
The age at which women present with breast cancer varies
between countries, but breast cancer generally is thought
to be more aggressive in younger women. The median age
of breast cancer presentation is much younger in many
Asian countries.5-7 We found that 27.4% of our institutional
cohort was younger than 40 years, which is comparable to
ﬁndings of other studies from Pakistan,13,14 and is a higher
rate than the 5% to 21% reported in many Western, Af-
rican, and Asian studies.5,6,15 Indeed, the median age at
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FIG 1. Age distribution of Pak-
istani versus US population. Teal
bars show distribution from Aga
Khan University (AKU); red bars
show distribution from National
Cancer Database (NCDB).
TABLE 1. Clinicopathologic Features of Younger and Older Patients With Breast Cancer in Pakistan
Characteristic
Patients Age £ 40
(n = 366)
Patients Age > 40
(n = 968) P
Patient age, median, years 35 54
Tumor stage , .001
0 6 (1.6) 24 (2.5) .115
I 10 (2.7) 99 (10.2) , .001
II 157 (42.9) 418 (43.2) .925
III 143 (39.1) 319 (33.0) .045
IV 48 (13.1) 105 (10.8) .246
Lymph node positive 256 (70.9) 549 (57.5) , .001
Tumor grade , .001
I 12 (3.8) 82 (9.8) .001
II 178 (56.2) 521 (62) .090
III 127 (40.1) 238 (28.3) , .001
Hormone receptor positive 223 (60.9) 697 (72) , .001
HER2 positive 84 (31.8) 242 (32.2) .914
Triple hormone receptor negative 67 (25.4) 106 (14.1) , .001
NOTE. Data given as no. (%) unless otherwise indicated.
Abbreviation: HER2, human epidermal growth factor receptor 2.
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diagnosis in the NCDB population was a decade older than
in the Pakistani cohort, and only 6% of patients in the
NCDB received their breast cancer diagnosis at age
younger than 40 years. Two reasons may explain these
differences. First, in Western countries like the United
States, older women (. 40 years of age) are routinely
screened with mammography, thereby increasing the de-
tection of breast cancer in older women. Second, the life
expectancy of women in Pakistan is signiﬁcantly lower than
that of women in the United States (67.4 v 81.0 years,
respectively) and the birth rate is signiﬁcantly higher (3.5 v
1.8 births per woman, respectively), resulting in a younger
female population in the country. This alone could explain
some of the differences in age distribution of breast cancer
across the two populations. Differences in genetic and
environmental exposures between the two populations
could also contribute to these differences; however, data in
this realm are lacking.
We found that younger patients in Pakistan weremore likely
to present at an advanced stage of breast cancer, with more
lymph node–positive disease, compared with older women.
These ﬁndings echo those of others who have studied this
concept in other countries. For example, the study by
Kroman et al16 of 10,356 women from Denmark found that
patients with breast cancer who were younger than
35 years had a higher rate of lymph node positivity com-
pared with older women in the study (51% v 46%; P = .02).
Similar results were published by Gajdos et al17 from the
United States, where women younger than 36 years had
larger tumor size with more lymph node involvement; these
patients were likely to present with stage II or III disease
than were their older counterparts (60% v 43%; P, .001).
Although some have argued that younger patients may
present with more advanced disease because of a lack of
awareness and screening, others have speculated this may
be because younger patients tend to present with bi-
ologically worse disease.18 Indeed, younger patients in our
institutional cohort, who were not screened, also tended to
present with higher-grade tumors that were more likely to
be triple hormone receptor–negative. Our study provides
TABLE 2. Comparison of Clinicopathologic Factors Between Patients in the AKUH and NCDB Cohorts Who Were Younger Than 40 Years of Age
Characteristic
Cohort, No. (%) P
AKUH NCDB NCDB IP AKUH v NCDB AKUH v NCDB IP
Tumor stage , .001 , .001
0 6 (1.6) 18,455 (16.7) 190 (16.6)
I 10 (2.7) 30,862 (27.9) 308 (26.9)
II 157 (42.9) 39,752 (35.9) 428 (37.4)
III 143 (39.1) 16,493 (14.9) 172 (15.0)
IV 48 (13.1) 5,171 (4.7) 47 (4.1)
Lymph node positive 256 (70.9) 21,932 (27.0) 272 (28.7) , .001 , .001
Grade 3 127 (40.1) 57,065 (55.5) 587 (56.9) , .001 , .001
Hormone receptor positive 223 (60.9) 75,995 (71.6) 769 (70.1) , .001 , .001
Triple hormone receptor negative 67 (25.4) 8,015 (7.6) 116 (10.9) , .001 , .001
Abbreviations: AKUH, Aga Khan University Hospital; IP, Indo-Pakistani origin; NCDB, National Cancer Database.
TABLE 3. Comparison of Clinicopathologic Factors Between Patients in the AKUH and NCDB Cohorts Who Were Older Than 40 Years of Age
Characteristic
Cohort, No. (%) P
AKUH NCDB NCDB IP AKUH v NCDB AKU v NCDB IP
Tumor stage , .001 , .001
0 24 (2.5) 384,858 (21.0) 1,658 (23.1)
I 99 (10.2) 756,132 (41.3) 2,613 (36.5)
II 418 (43.2) 456,223 (24.9) 1,923 (26.8)
III 319 (33.0) 161,018 (8.8) 702 (9.8)
IV 105 (10.8) 70,815 (3.9) 272 (3.8)
Lymph node positive 549 (57.5) 179,420 (13.2) 912 (16.3) , .001 , .001
Grade 3 238 (28.3) 569,598 (34.2) 2,414 (38.1) , .001 , .001
Hormone receptor positive 697 (72.0) 1,435,300 (82.6) 5,434 (80.3) , .001 , .001
Triple hormone receptor negative 106 (14.1) 77,698 (4.5) 373 (5.7) , .001 , .001
Abbreviations: AKUH, Aga Khan University Hospital; IP, Indo-Pakistani origin; NCDB, National Cancer Database.
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a comparison between the Pakistani and US populations,
and may provide some insight into this dichotomy. In
Pakistan, widespread screening is not available, even for
older patients. This has not changed over the 12 years
during which our institutional cohort was studied, whereas
in the United States, screening is widely available for pa-
tients older than 40 years. Patients older than 40 years in
the Pakistani cohort presented at a later stage of disease
than did patients in the NCDB, suggesting that screening
may have an impact. However, this was also the case in the
younger cohort, in which routine screening would not play
a role, even in the American population. Furthermore, that
triple-negative breast cancer is three-fold more common in
patients in Pakistan than in the United States, regardless of
age cohort, suggests some fundamental differences in the
biology of the disease between the two cohorts. Whether
this is related to genetic or other factors is unknown.
Our ﬁndings when comparing patients of Indo-Pakistani
origin with other races in the NCDB would support this
hypothesis. In the older cohort, for whom screening is
largely available, those of Indo-Pakistani origin tended to
present with later-stage disease, with more high-grade,
triple-negative tumors. Whether this is due to a reluctance
to undergo screening, worse biology, or both is unclear.
However, in the younger American cohort, for whom
screening is not widely available, patients of Indo-Pakistani
origin present at the same stage of disease as their
non–Indo-Pakistani American counterparts. However, the
incidence of triple hormone receptor–negative disease is
greater in the former group. The etiology of this ﬁnding,
which seems to be ubiquitous across countries and age
groups, remains to be elucidated.
Interestingly, the AKUH cohort tended to have fewer high-
grade breast cancers compared with the NCDB cohort.
However, this may not necessarily reﬂect more favorable
biology in the Pakistani cohort; rather, it may reﬂect the
subjectivity with which grading of breast cancer is done.
Pakistani patients were also less likely to have low-grade
tumors, compared with their American counterparts
(younger cohort, 3.8% v 9.5%, P , .001; older cohort,
9.8% v 22.4%, P , .001). Overall, 60% of the Pakistani
cases were classiﬁed as intermediate grade, whereas the
proportion of patients in this category in the US population
was 43% (P , .001).
To our knowledge, this is the only study performed of young
Pakistani women to date in which tumor stage and biology
were compared with a control population of older women.
Our study should be viewed in light of some limitations. This
was a single-center, retrospective study and Pakistani
patients at AKUH may not reﬂect women from all parts of
the country. Still, our data have face validity. As in many
parts of the developing world, there seems to be a dispro-
portionate number of younger patients with breast cancer
in Pakistan compared with more industrialized countries.
As noted across populations, younger patients tend to
present with higher-stage, lymph node–positive disease
and are more likely to have triple hormone receptor–
negative disease. However, we found that patients with
breast cancer in Pakistan tended to present with higher-
stage, lymph node–positive, endocrine-resistant, triple-
negative tumors compared with their US counterparts re-
gardless of age at presentation. Our comparison of US
patients of Indo-Pakistani origin and their other US
counterparts further strengthens the hypothesis that dif-
ferences in presentation of breast cancer across pop-
ulations are multifactorial in etiology and not solely due to
differences in screening alone. Additional effort to evaluate
potential causes of worse biology is required.
TABLE 4. Comparison of Indo-Pakistani Patients With Other Races in the National Cancer Database
Characteristic
Younger Cohort (£ 40 years) Older Cohort (> 40 years)
IP Other Races P IP Other Races P
Tumor stage .748 , .001
0 190 (16.6) 18,265 (16.7) 1,658 (23.1) 383,200 (21.0)
I 308 (26.9) 30,554 (27.9) 2,613 (36.5) 753,518 (41.4)
II 428 (37.4) 39,324 (35.9) 1,923 (26.8) 454,300 (24.9)
III 172 (15.0) 16,321 (14.9) 702 (9.8) 160,316 (8.8)
IV 47 (4.1) 5,124 (4.7) 272 (3.8) 70,543 (3.9)
Lymph node positive 272 (28.7) 21,863 (27.2) .858 912 (16.3) 180,195 (13.3) , .001
Grade 3 587 (56.9) 57,065 (55.5) .053 2,414 (38.1) 548,992 (33.5) , .001
Hormone receptor positive 769 (70.1) 75,226 (71.6) .564 5,434 (80.3) 1,429,866 (82.6) , .001
Triple hormone receptor negative 116 (10.9) 7,899 (7.5) , .001 373 (5.7) 77,325 (4.5) , .001
NOTE. Data given as no. (%) unless otherwise indicated.
Abbreviation: IP, Indo-Pakistani origin.
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